RAPH (Raphael Pharmaceutical) Total Operating Expense: $1.04 Mil (TTM As of Mar. 2026)


RAPH Raphael Pharmaceutical Inc RAPH
37 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Raphael Pharmaceutical Total Operating Expense?

Raphael Pharmaceutical RAPH 37 Total Operating Expense is $1.04 Mil as of Mar. 2026. GuruFocus rates RAPH with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Raphael Pharmaceutical's Total Operating Expense for the three months ended in Mar. 2026 was $0.22 Mil. Raphael Pharmaceutical's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $1.04 Mil.

Raphael Pharmaceutical Total Operating Expense Related Terms

Raphael Pharmaceutical Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Raphael Pharmaceutical's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raphael Pharmaceutical Total Operating Expense Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 1.63 3.32 1.33 1.51 1.25

Raphael Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.32 0.25 0.25 0.22
RAPH
37GF Score
Raphael Pharmaceutical Inc RAPH
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Raphael Pharmaceutical Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $1.04 Mil mean?
Raphael Pharmaceutical (RAPH) has a Total Operating Expense of $1.04 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Raphael Pharmaceutical and its competitors.
Is Raphael Pharmaceutical's Total Operating Expense too high?
Raphael Pharmaceutical's current Total Operating Expense is $1.04 Mil. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's Total Operating Expense compare to TXMD and AYTU?
Raphael Pharmaceutical's Total Operating Expense of $1.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Raphael Pharmaceutical and its competitors. Raphael Pharmaceutical's current Total Operating Expense is $1.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current Total Operating Expense of $1.04 Mil. The current Total Operating Expense is $1.04 Mil. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current Total Operating Expense is $1.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Raphael Pharmaceutical Business Description

Address 4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score

Get the complete analysis for RAPH

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price